These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32207130)

  • 1. [Dilemmas in discontinuation of antipsychotic drug use in people with intellectual disabilities].
    de Kuijper G; Ramerman L; Jonker J; Hoekstra PJ
    Tijdschr Psychiatr; 2020; 62(3):203-212. PubMed ID: 32207130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability.
    de Kuijper GM; Hoekstra PJ
    J Intellect Disabil Res; 2017 Oct; 61(10):899-908. PubMed ID: 28560761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open-Label Discontinuation Trial of Long-Term, Off-Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure.
    de Kuijper GM; Hoekstra PJ
    J Clin Pharmacol; 2018 Nov; 58(11):1418-1426. PubMed ID: 29920689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability.
    de Kuijper G; Evenhuis H; Minderaa RB; Hoekstra PJ
    J Intellect Disabil Res; 2014 Jan; 58(1):71-83. PubMed ID: 23046144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open label discontinuation trial of long-term used off-label antipsychotic drugs in people with intellectual disability: The influence of staff-related factors.
    de Kuijper GM; Hoekstra PJ
    J Appl Res Intellect Disabil; 2019 Mar; 32(2):313-322. PubMed ID: 30264420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Practical guidelines for prescribing psychotropic medication to people with intellectual disability].
    de Kuijper G; Degraeve G; Zinkstok JR
    Tijdschr Psychiatr; 2019; 61(11):786-791. PubMed ID: 31907889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
    Deb S; Unwin G; Deb T
    J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of psychotropic medication and factors associated with antipsychotic treatment in adults with intellectual disabilities: a cross-sectional, epidemiological study in Germany.
    Koch AD; Dobrindt J; Schützwohl M
    J Intellect Disabil Res; 2021 Feb; 65(2):186-198. PubMed ID: 33393123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Health-Related Quality of Life in People With Intellectual Disabilities Who Discontinue Long-Term Used Antipsychotic Drugs for Challenging Behaviors.
    Ramerman L; Hoekstra PJ; de Kuijper G
    J Clin Pharmacol; 2019 Feb; 59(2):280-287. PubMed ID: 30161270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial.
    Beumer S; Hamers P; Oppewal A; Maes-Festen D
    BMC Psychiatry; 2021 Sep; 21(1):439. PubMed ID: 34488701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Psychotropic drug prescription to people with intellectual disability in GP practices].
    Bakker-van Gijssel EJ; Leusink GL
    Ned Tijdschr Geneeskd; 2015; 159():A9754. PubMed ID: 26629605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypharmacy in the treatment of subjects with intellectual disability.
    Häβler F; Thome J; Reis O
    J Neural Transm (Vienna); 2015 Aug; 122 Suppl 1():S93-100. PubMed ID: 24858727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and patterns of anti-epileptic medication prescribing in the treatment of epilepsy in older adults with intellectual disabilities.
    O'Dwyer M; Peklar J; Mulryan N; McCallion P; McCarron M; Henman MC
    J Intellect Disabil Res; 2018 Mar; 62(3):245-261. PubMed ID: 29314463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services.
    Paton C; Flynn A; Shingleton-Smith A; McIntyre S; Bhaumik S; Rasmussen J; Hardy S; Barnes T
    J Intellect Disabil Res; 2011 Jul; 55(7):665-74. PubMed ID: 21507097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.
    Sheehan R; Hassiotis A; Walters K; Osborn D; Strydom A; Horsfall L
    BMJ; 2015 Sep; 351():h4326. PubMed ID: 26330451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychotropic drug use among people with intellectual disability before and after deinstitutionalization.
    Nøttestad JA; Linaker OM
    J Intellect Disabil Res; 2003 Sep; 47(Pt 6):464-71. PubMed ID: 12919197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawing Antipsychotics for Challenging Behaviours in Adults with Intellectual Disabilities: Experiences and Views of Prescribers.
    de Kuijper G; de Haan J; Deb S; Shankar R
    Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotropic drugs intake in people aging with intellectual disability: Prevalence and predictors.
    García-Domínguez L; Navas P; Verdugo MÁ; Arias VB; Gómez LE
    J Appl Res Intellect Disabil; 2022 Sep; 35(5):1109-1118. PubMed ID: 35384179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study.
    Ramerman L; de Kuijper G; Scheers T; Vink M; Vrijmoeth P; Hoekstra PJ
    J Intellect Disabil Res; 2019 May; 63(5):418-428. PubMed ID: 30609152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.